University of Manchester, Medicines Evaluation Unit, Manchester Academic Health Sciences Centre, University Hospital of South Manchester, Manchester, UK.
Int Immunopharmacol. 2012 Jul;13(3):225-31. doi: 10.1016/j.intimp.2012.04.008. Epub 2012 May 2.
LPS inhalation was used to investigate whether sputum supernatant post-LPS challenge increases neutrophil chemotactic activity and to elucidate the role of CXCR1/CXCR2 signalling in this process. 14 healthy non-smoking subjects inhaled 30μg of LPS. Sputum was induced at baseline, 6 and 24h post-LPS challenge. Differential cell counts were determined and supernatants CXCL8, CXCL1, IL-6 and CCL2 levels measured. Peripheral blood neutrophils obtained from healthy volunteers were used for chemotaxis experiments using sputum supernatant. To delineate signalling mechanisms, the effects of a CXCR2/CXCR1 (dual) antagonist (Sch527123) and a CXCR2 specific antagonist (SB656933) were tested. LPS inhalation significantly increased sputum neutrophil counts from 45.3% to 76.7% and 69.3% at 6 and 24h respectively. LPS increased CXCL8, IL-6 and CCL2 levels but not CXCL1. Neutrophil chemotaxis significantly increased (2.7 fold) at 24h compared to baseline. Chemotaxis was inhibited by 79.0% with Sch527123 and 52.0% with SB656933. We conclude that LPS challenge increases sputum supernatant CXCL8 levels, which is associated with increased chemotactic activity which is dependent on both CXCR1 and CXCR2.
LPS 吸入被用于研究 LPS 挑战后痰液上清液是否会增加中性粒细胞趋化活性,并阐明 CXCR1/CXCR2 信号在这一过程中的作用。14 名健康不吸烟的受试者吸入 30μg LPS。在 LPS 挑战前、后 6 小时和 24 小时采集痰液。测定差异细胞计数,并测量上清液中 CXCL8、CXCL1、IL-6 和 CCL2 的水平。从健康志愿者中获得外周血中性粒细胞,用于使用痰液上清液进行趋化实验。为了阐明信号机制,测试了 CXCR2/CXCR1(双重)拮抗剂(Sch527123)和 CXCR2 特异性拮抗剂(SB656933)的作用。LPS 吸入使痰液中性粒细胞计数分别从 45.3%增加到 76.7%和 69.3%,分别在 6 小时和 24 小时。LPS 增加了 CXCL8、IL-6 和 CCL2 的水平,但没有增加 CXCL1。与基线相比,24 小时中性粒细胞趋化性显著增加(增加 2.7 倍)。Sch527123 抑制趋化性 79.0%,SB656933 抑制 52.0%。我们得出结论,LPS 挑战增加了痰液上清液中 CXCL8 的水平,这与趋化活性的增加有关,而趋化活性依赖于 CXCR1 和 CXCR2。